WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ Inc. (NASDAQ: BIVV) will report its financial results for the first quarter ending March 31, 2017 on Wednesday, May 3, 2017, after the market closes. The press release will be available in the "Investor Relations" section of the company's website at investors.bioverativ.com.
On Thursday, May 4, 2017 at 8:00 a.m. EDT, the Company will host a live webcast where Bioverativ management will discuss the financial results. To access the live webcast, please visit Bioverativ’s Investors page at investors.bioverativ.com. An archived version of the webcast will be available following the presentation.
Bioverativ (NASDAQ: BIVV) is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter.
Susan Altschuller, +1 781-663-4360